natgillin/translations-raw huggingface dataset:
Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of Symtuza treatment. 
U bolesnika s podležećim kroničnim hepatitisom, cirozom, ili u bolesnika koji su prije liječenja imali povišene vrijednosti transaminaza potrebno je razmotriti pojačano praćenje vrijednosti AST-a/ALT-a, osobito u prvih nekoliko mjeseci liječenja lijekom Symtuza.
Following oral administration of Symtuza, the median terminal elimination half-life of emtricitabine is 17.2 hours. 
Medijan terminalnog poluvijeka eliminacije emtricitabina nakon peroralne primjene lijeka Symtuza iznosi 17,2 sata.
Lipid disorders should be managed as clinically appropriate. 
Poremećaje vrijednosti lipida treba liječiti prema kliničkoj potrebi.
Co-administration of cobicistat with medicinal products that are substrates of these transporters can result in increased plasma concentrations of the co-administered medicinal products. 
Istodobna primjena kobicistata s lijekovima koji su supstrati ovih prijenosnika može uzrokovati povišenje plazmatskih koncentracija istodobno primijenjenih lijekova.
A trial of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with severe renal impairment (eGFRCG below 30 mL/min). 
Ispitivanje farmakokinetike kobicistata provedeno je u ispitanika s teškim oštećenjem bubrežne funkcije koji nisu bili zaraženi virusom HIV-1 (eGFRCG ispod 30 ml/min).
No virologic data 
Nema viroloških podatka Razlozi
Patients should be informed that dizziness may occur when treated with Symtuza (see section 4.8). 
Bolesnike treba upozoriti da se tijekom liječenja lijekom Symtuza može javiti omaglica (vidjeti dio 4.8).
It is not recommended to co-administer Symtuza with glecaprevir/pibrentasvir. 
Ne preporučuje se istodobna primjena lijeka Symtuza s glekaprevirom/pibrentasvirom.
Using Cyst C as filtration marker, the median changes in estimated glomerular filtration rate calculated using the CKD-EPI (eGFRCKD-EPI CystC) formula were respectively 4.0 mL/min/1.73 m² and 1.6 mL/min/1.73 m² (p<0.001). 
Koristeći cistatin C kao biljeg filtracije utvrđeno je da je medijan promjene procijenjene brzine glomerularne filtracije izračunate jednadžbom CKD-EPI (eGFRCKD-EPI CystC) iznosio 4,0 ml/min/1,73 m² odnosno 1,6 ml/min/1,73 m² (p = 0,001).
C]-cobicistat, 86% and 8.2% of the dose were recovered in feces and urine, respectively. 
C]-kobicistata 86% doze pronađeno je u fecesu, a 8,2% u mokraći.
The safety of Symtuza in paediatric patients has not been investigated. 
Sigurnost lijeka Symtuza nije se ispitivala u pedijatrijskih bolesnika.
The median terminal elimination half-life of tenofovir alafenamide was 0.3 hours when administered as Symtuza. 
Medijan terminalnog poluvijeka eliminacije tenofoviralafenamida nakon primjene lijeka Symtuza iznosio je 0,3 sata.
The most frequent (> 5%) adverse reactions reported in treatment-naïve patients in the Phase 2 (GSUS-299-0102) and Phase 3 Study (AMBER, TMC114FD2HTX3001, Week 96 analysis) were diarrhoea (22.6%), headache (13.1%), rash (12.7%), nausea (9.7%), fatigue (8.0%), and abdominal pain (5.8%). 
Najčešće nuspojave (> 5%) prijavljene u bolesnika koji prethodno nisu bili liječeni u ispitivanju faze 2 (GS-US-299-0102) i ispitivanju faze 3 (AMBER, TMC114FD2HTX3001, analiza u 96. tjednu) bile su proljev (22,6%), glavobolja (13,1%), osip (12,7%), mučnina (9,7%), umor (8,0%) i bol u abdomenu
However,the safety of components of Symtuza was evaluated through the clinical study TMC114-C230 (N = 12) for darunavir with ritonavir and GS-US-292-0106 (N = 50) for a fixed dose combination containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. 
Međutim, sigurnost pojedinačnih sastavnica lijeka Symtuza ocjenjivala se u kliničkom ispitivanju TMC114-C230 (N = 12), u kojem se ocjenjivao darunavir u kombinaciji s ritonavirom, te u ispitivanju GS-US-292-0106 (N = 50), u kojem se ocjenjivala fiksna kombinacija doza elvitegravira, kobicistata, emtricitabina i tenofoviralafenamida.
What Symtuza looks like and contents of the pack Yellow to yellowish-brown capsule shaped film-coated tablet, mentioning “8121” on one side and “JG” on the other side. 
Žuta do žućkasto-smeđa filmom obložena tableta u obliku kapsule, s utisnutom oznakom “8121” na jednoj strani i “JG” na drugoj strani.
In some patients with advanced HIV infection and who had unusual infections due to a weakened immune system (opportunistic infection), signs and symptoms of inflammation from previous infections may occur soon after you start HIV treatment. 
U nekih bolesnika s uznapredovalom HIV infekcijom koji su zbog oslabljenog imunološkog sustava već imali neuobičajene infekcije (oportunističke infekcije) mogu se ubrzo nakon početka liječenja HIV-a pojaviti znakovi i simptomi upale od prijašnjih infekcija.
One film-coated tablet of Symtuza once daily taken with food may be used in patients with prior exposure to antiretroviral medicinal products but without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/mL and CD4+ cell count ≥ 100 cells x 10 
Bolesnici koji su prethodno primali antiretrovirusnu terapiju Jednu filmom obloženu tabletu lijeka Symtuza uzetu jedanput dnevno s hranom mogu koristiti bolesnici koji su prethodno bili izloženi antiretrovirusnim lijekovima, ali bez mutacija povezanih s rezistencijom na darunavir (DRV-RAM-ovi)* i s HIV-1 RNK < 100 000 kopija/ml te brojem stanica CD4+ ≥ 100 stanica x 10
Simeprevir may increase darunavir and/or cobicistat plasma concentrations. 
Simeprevir može povisiti plazmatske koncentracije darunavira i/ili kobicistata.
The median terminal plasma half-life of darunavir following administration of Symtuza is 5.5 hours. 
Medijan terminalnog poluvijeka darunavira u plazmi nakon primjene lijeka Symtuza iznosi 5,5 sati.
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by therapeutic areas 
INTERAKCIJE I PREPORUKE ZA DOZIRANJE KOD PRIMJENE S DRUGIM LIJEKOVIMA
Tell your doctor if you take: - Alfentanil (injectable, strong and short-acting, painkiller that is used for surgical procedures) - Carvedilol, metoprolol, timolol (for heart disease) - Warfarin (to reduce clotting of the blood) as its therapeutic effect or side effects may be altered; 
Obavijestite liječnika ako uzimate: - alfentanil (u obliku injekcije, jaki i kratkodjelujući lijek za liječenje boli koji se koristi u kirurškim zahvatima) - karvedilol, metoprolol, timolol (za srčanu bolest) - varfarin (za smanjenje zgrušavanja krvi), zbog mogućih promjena njegova terapijskog učinka ili nuspojava; liječnik će Vam možda trebati provjeriti krvnu sliku.
• If you notice 12 hours or more after the time you usually take Symtuza, then do not take the missed dose and take the next doses with food at your usual time. 
• Ako primijetite da ste propustili uzeti lijek 12 ili više sati nakon uobičajenog vremena uzimanja lijeka Symtuza, preskočite propuštenu dozu i uzmite iduću dozu s hranom prema uobičajenom rasporedu.
Therefore, co-administration of Symtuza and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). 
Stoga je kontraindicirana istodobna primjena lijeka Symtuza i sildenafila kada se primjenjuje za liječenje plućne arterijske hipertenzije (vidjeti dio 4.3).
ANTACIDS Aluminium/magnesium hydroxide 
Aluminijev/magnezijev hidroksid Kalcijev karbonat
• muscle pain, muscle cramps or weakness 
• bol u mišićima, grčenje ili slabost u mišićima
Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, abdominal distension, dyspepsia, flatulence uncommon pancreatitis acute, pancreatic enzymes increased 
Poremećaji probavnog sustava vrlo često proljev često povraćanje, mučnina, bol u abdomenu, distenzija abdomena, dispepsija, flatulencija manje često akutni pankreatitis, povišene vrijednosti gušteračnih enzima
If you vomit within 1 hour of taking the medicine, another dose of Symtuza should be taken with food as soon as possible. 
Ako povratite unutar sat vremena od uzimanja lijeka, trebate uzeti još jednu dozu lijeka Symtuza što je prije moguće, s hranom.
Darunavir and cobicistat 
Darunavir i kobicistat
Co-administration of tenofovir alafenamide with other medicinal products that inhibit P-gp (e.g., cobicistat, ritonavir, ciclosporin) are expected to increase the absorption and plasma concentration of tenofovir alafenamide. 
Očeukje se da će istodobna primjena tenofoviralafenamida i drugih lijekova koji inhibiraju P-gp (npr. kobicistata, ritonavira, ciklosporina) povećati apsorpciju i plazmatske koncentracije tenofoviralafenamida.
Based on theoretical considerations boceprevir may decrease darunavir and/or cobicistat plasma concentrations and adversely affect the intracellular activation and clinical antiviral efficacy of tenofovir alafenamide. 
Na temelju teorijskih razmatranja, boceprevir bi mogao sniziti plazmatske koncentracije darunavira i/ili kobicistata te štetno utjecati na unutarstaničnu aktivaciju i kliničku antivirusnu djelotvornost tenofoviralafenamida.
For these neuroleptics, consider reducing the dose of the neuroleptic upon co-administration with Symtuza. 
Kod istodobne primjene ovih neuroleptika s lijekom Symtuza razmotrite smanjenje doze neuroleptika.
Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. 
Trinaest posto (13%) doze emtricitabina pronađeno je mokraći u obliku tri metabolita.
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR Apixaban 
ANTIKOAGULANSI/INHIBITORI AGREGACIJE TROMBOCITA
No emergent resistance to E/C/F/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) was detected through Week 48. 
48. tjedna nije opažena pojava rezistencije na E/K/F/TAF (elvitegravir/kobicistat/emtricitabin/ tenofoviralafenamid).
Darunavir demonstrates antiviral activity in vitro against a broad panel of HIV-1 group M (A, B, C, D, E, F, G) and group O primary isolates with EC50 values ranging from < 0.1 to 4.3 nM. 
Darunavir pokazuje antivirusnu aktivnost in vitro protiv širokog raspona primarnih izolata virusa HIV-1 skupine M (A, B, C, D, E, F, G) i skupine O, uz vrijednosti EC50 u rasponu od < 0,1 do 4,3 nM.
No clinically relevant pharmacokinetic differences due to age have been identified for cobicistat, emtricitabine or tenofovir alafenamide in the age range ≤ 65 years. 
Nisu utvrđene klinički značajne dobno uvjetovane farmakokinetičke razlike za kobicistat, emtricitabin ni tenofoviralafenamid u rasponu dobi ≤ 65 godina.
Co-administration with the following medicinal products due to the potential for serious and/or life-threatening adverse reactions (see section 4.5): - alfuzosin - amiodarone, dronedarone, ivabradine, quinidine, ranolazine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - rifampicin - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - dapoxetine - domperidone - naloxegol - pimozide, quetiapine, sertindole, lurasidone (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam, 
Istodobna primjena sa sljedećim lijekovima zbog mogućih ozbiljnih i/ili po život opasnih nuspojava (vidjeti dio 4.5): - alfuzozin - amiodaron, dronedaron, ivabradin, kinidin, ranolazin - kolhicin, kada se koristi u bolesnika s oštećenjem bubrežne i/ili jetrene funkcije (vidjeti dio 4.5) - rifampicin - derivati ergota (npr. dihidroergotamin, ergometrin, ergotamin, metilergonovin) - dapoksetin - domperidon - naloksegol - pimozid, kvetiapin, sertindol, lurazidon (vidjeti dio 4.5) - triazolam, peroralno primijenjen midazolam (za mjere opreza pri parenteralnoj primjeni midazolama vidjeti dio 4.5) - sildenafil, kada se koristi za liječenje plućne arterijske hipertenzije, avanafil, simvastatin,
Week 48 and 96 Virologic Outcomes in EMERALD Trial Week 48 
Tablica 6: Virološki ishodi u 48. i 96. tjednu EMERALD ispitivanja 48. tjedan
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine. 
Emtricitabin je nukleozidni inhibitor reverzne transkriptaze (engl. nucleoside reverse transcriptase inhibitor, NRTI) i nukleozidni analog 2'-doksicitidina.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection (unusual infections due to a weakened immune system), signs and symptoms of inflammation from previous infections may occur soon after HIV treatment is started, including Symtuza. 
U nekih bolesnika s uznapredovalom HIV infekcijom (SIDA) koji su već imali oportunističke infekcije (neuobičajene infekcije zbog oslabljenog imunološkog sustava) mogu se ubrzo nakon početka primjene lijeka za HIV, uključujući lijek Symtuza, pojaviti znakovi i simptomi upale od prijašnjih infekcija.
Methylergonovine 
Metilergonovin
The median increases from baseline were greater in the D/C/F/TAF group compared with the DRV/ cobicistat (COBI)+F/ tenofovir disoproxil fumarate (TDF) group at Week 48. 
Medijani povišenja od početnih vrijednosti bili su veći u skupini koja se liječila kombinacijom D/K/F/TAF nego u onoj koja je primala DRV/kobicistat (KOBI)+F/tenofovirdizoproksilfumarat (TDF) u 48. tjednu.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of cobicistat has not been studied. 
Utjecaj teškog oštećenja jetrene funkcije (Child-Pugh stadij C) na farmakokinetiku kobicistata nije ispitivan.
The median terminal plasma half-life of cobicistat following administration of Symtuza is 3.6 hours. 
Medijan terminalnog poluvijeka kobicistata u plazmi nakon primjene lijeka Symtuza iznosi 3,6 sati.
Contact your doctor or nearest emergency department immediately for advice. 
Ako uzmete više lijeka Symtuza nego što ste trebali Odmah se za savjet obratite svom liječniku ili najbližoj hitnoj službi.
Viruses selected in these conditions and showing decreased susceptibility to darunavir (range: 23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene. 
Izdvojeni virusi nisu mogli rasti u prisutnosti darunavira u koncentracijama iznad 400 nM. Virusi izdvojeni u tim uvjetima, koji su pokazivali smanjenu osjetljivost na darunavir (raspon: 23 - 50 puta), imali su 2 - 4 aminokiselinske supstitucije u genu proteaze.
The tablet core contains croscarmellose sodium, magnesium stearate, microcrystalline cellulose and colloidal silicon dioxide. 
Jezgra tablete sadrži umreženu karmelozunatrij, magnezijev stearat, mikrokristaličnu celulozu i koloidni silicijev dioksid.
• emtricitabine, an anti-HIV medicine known as a nucleoside reverse transcriptase inhibitor 
• emtricitabin, lijek za HIV poznat kao nukleozidni inhibitor reverzne transkriptaze
Using Cyst C as filtration marker, the median change in estimated glomerular filtration rate calculated using the CKD-EPI (eGFRCKD-EPI Cyst C) formula (N=22) was +4.4 mL/min/1.73 m² with D/C/F/TAF. 
Koristeći cistatin C kao biljeg filtracije utvrđeno je da je medijan promjene procijenjene brzine glomerularne filtracije izračunate jednadžbom CKD-EPI (eGFRCKD-EPI CystC) (N=22) iznosio +4,4 ml/min/1,73 m² uz D/K/F/TAF.
Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with Symtuza is not recommended. 
Ne preporučuje se istodobna primjena tadalafila za liječenje plućne arterijske hipertenzije i lijeka Symtuza.
Clinically relevant changes in tenofovir pharmacokinetics in patients with hepatic impairment were not observed in patients with mild to moderate hepatic impairment. 
Nisu primijećene klinički važne promjene u farmakokinetici tenofovira u bolesnika s blagim do umjerenim oštećenjem jetrene funkcije.
The bioavailability of all components of Symtuza was comparable to that when darunavir 800 mg, cobicistat 150 mg, and emtricitabine/tenofovir alafenamide 200/10 mg were co-administered as separate formulations; bioequivalence was established following single-dose administration under fed conditions in healthy subjects (N = 96). 
Bioraspoloživost svih sastavnica lijeka Symtuza bila je usporediva s onom kada su se darunavir u dozi od 800 mg, kobicistat u dozi od 150 mg i emtricitabin/tenofoviralafenamid u dozi od 200/10 mg primjenjivali istodobno kao zasebni lijekovi; bioekvivalentnost je utvrđena u zdravih ispitanika (N = 96) nakon primjene jedne doze na pun želudac.
Symtuza should not be used in paediatric patients below 3 years of age (see sections 4.2 and 5.3). 
Symtuza se ne smije primjenjivati u pedijatrijskih bolesnika mlađih od 3 godine (vidjeti dijelove 4.2 i
Symtuza and sofosbuvir, sofosbuvir/ledipasvir, or daclatasvir can be used concomitantly without dose adjustment 
Symtuza se može primjenjivati istodobno sa sofosbuvirom, kombinacijom sofosbuvir/ledipasvir ili daklatazvirom bez prilagodbe doze.
At baseline, median plasma HIV-1 RNA was 4.7 log10 copies/mL, median CD4+ cell count was 456 cells/mm 
Na početku ispitivanja medijan plazmatske vrijednosti HIV-1 RNK iznosio je 4,7 log10 kopija/ml, medijan broja CD4+ stanica 456 stanica/mm
• If you notice within 12 hours of the time you usually take Symtuza, you must take the tablet immediately, with food. 
• Ako primijetite da niste uzeli lijek unutar 12 sati od uobičajenog vremena uzimanja lijeka Symtuza, tabletu morate uzeti odmah s hranom.
OPIOID ANTAGONIST Naloxegol 
ANTAGONISTI OPIOIDA
• abnormal blood test results such as some tests for your kidney. 
• odstupanja u rezultatima krvnih pretraga, kao što su neke pretrage kojima se procjenjuje rad gušterače.
The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+-T lymphocytes. 
Antivirusna aktivnost tenofoviralafenamida protiv laboratorijskih i kliničkih izolata virusa HIV-1 iz skupine B ocjenjivala se na limfoblastoidnim staničnim linijama, mononuklearnim stanicama iz periferne krvi, primarnim monocitnim/makrofagnim stanicama i CD4+ T-limfocitima.
In the study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50 HIV-1 infected, treatment-naïve adolescents received emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. 
Djelotvornost, sigurnost i farmakokinetika emtricitabina i tenofoviralafenamida ocjenjivale su se u otvorenom ispitivanju (GS-US-292-0106) u kojem je 50 prethodno neliječenih adolescenata zaraženih virusom HIV-1 primalo emtricitabin i tenofoviralafenamid (10 mg) zajedno s elvitegravirom i kobicistatom u tableti s fiksnom kombinacijom doza.
Included subjects who had HIV-1 RNA ≥ 50 copies/mL in the Week 48/96 window; subjects who discontinued early due to lack or loss of efficacy per investigator's assessment; subjects who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a HIV-1 RNA ≥ 50 copies/mL. 
Uključeni ispitanici koji su imali HIV-1 RNK ≥50 kopija/mL u rasponu oko 48./96. tjedna; ispitanici koji su prerano prekinuli liječenje radi nedostatka ili gubitka djelotvornosti prema procjeni ispitivača; ispitanici koji su prekinuli liječenje zbog drugih razloga osim nuspojava, smrti ili nedostatka ili gubitka djelotvornosti i u vrijeme prekida uzimanja lijeka su imali HIV-1 RNK ≥ 50 kopija/mL.
If a dose of Symtuza is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of Symtuza with food as soon as possible. 
Ako bolesnik propusti uzeti dozu lijeka Symtuza i primijeti to unutar 12 sati od uobičajenog vremena uzimanja, treba ga uputiti da propisanu dozu lijeka Symtuza uzme što prije s hranom.
C]-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of [ 
C]-darunavira pojačanog ritonavirom u dozi od 400/100 mg približno 79,5%
Croscarmellose sodium Magnesium stearate Cellulose, microcrystalline Silica, colloidal anhydrouse 
Karmelozanatrij, umrežena Magnezijev stearat Celuloza, mikrokristalična Silicijev dioksid, koloidni, bezvodni
Symtuza and antacids can be used concomitantly without dose adjustment. 
Symtuza se može primjenjivati istodobno s antacidima bez prilagodbe doze.
Caution should be used with co-administration of Symtuza and parenteral midazolam. 
Nužan je oprez pri istodobnoj primjeni lijeka Symtuza i parenteralno primijenjenog midazolama.
Each film-coated tablet contains 800 mg darunavir (as ethanolate), 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (as fumarate). 
Jedna filmom obložena tableta sadrži 800 mg darunavira (u obliku darunaviretanolata), 150 mg kobicistata, 200 mg emtricitabina i 10 mg tenofoviralafenamida (u obliku tenofoviralafenamidfumarata).
Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 μM). 
Emtricitabin je u staničnoj kulturi pokazao antivirusnu aktivnost protiv virusa HIV-1 iz skupina A, B, C, D, E, F i G (vrijednosti EC50 kretale su se u rasponu od 0,007 do 0,075 µM) i aktivnost protiv određenih sojeva virusa HIV-2 (vrijednosti EC50 kretale su se u rasponu od 0,007 do 1,5 µM).
If you vomit more than 1 hour after taking the medicine, then you do not need to take another dose of Symtuza until the next regularly scheduled time. 
Ako povratite nakon sat vremena od uzimanja lijeka, ne trebate uzeti još jednu dozu lijeka Symtuza prije sljedeće doze prema uobičajenom rasporedu.
It is not known whether darunavir, cobicistat, or tenofovir alafenamide are excreted in human milk. 
Nije poznato izlučuju li se darunavir, kobicistat ili tenofoviralafenamid u majčino mlijeko.
Janssen-Cilag A/S Tlf: +45 45 94 82 82 jacdk@its.jnj.com 
Danmark Janssen-Cilag A/S Tlf: +45 45 94 8282 jacdk@its.jnj.com
Amiodarone, dronedarone, ivabradine, quinidine, or ranolazine to treat certain heart disorders (e.g. abnormal heart rhythm) 
Namjena lijeka alfuzozin za liječenje povećane prostate amiodaron, dronedaron, ivabradin, kinidin ili ranolazin za liječenje određenih srčanih poremećaja (npr. nepravilnog srčanog ritma)
Thioridazine 
Tioridazin
• tenofovir alafenamide, an anti-HIV medicine known as a nucleotide reverse transcriptase inhibitor 
• tenofoviralafenamid, lijek za HIV poznat kao nukleotidni inhibitor reverzne transkriptaze
Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. 
Tenofovir se unutar stanice naknadno fosforilira u farmakološki aktivan metabolit tenofovirdifosfat.
Concomitant use of salmeterol and Symtuza is not recommended. 
Ne preporučuje se istodobna primjena salmeterola i lijeka Symtuza.
Cobicistat is not expected to induce CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1, or P-gp (MDR1). 
Ne očekuje se da će kobicistat inducirati CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1 ili P-gp (MDR1).
• abnormal blood test results such as some tests for your pancreas. 
• odstupanja u rezultatima krvnih pretraga, kao što su nalazi testova kojima se ocjenjuje rad bubrega.
Co-administration of domperidone with Symtuza is contraindicated. 
Istodobna primjena domperidona s lijekom Symtuza je kontraindicirana.
No clinically relevant pharmacokinetic differences due to gender have been identified for cobicistat, emtricitabine or tenofovir alafenamide. 
Nisu utvrđene klinički značajne spolom uvjetovane farmakokinetičke razlike za kobicistat, emtricitabin ni tenofoviralafenamid.
Based on theoretical considerations Symtuza is expected to increase concentrations of clonazepam (inhibition of CYP3A) 
Temeljeno na teorijskim postavkama očekuje se da će Symtuza povećati koncentracije klonazepama (CYP3A inhibicija)
Non-clinical data on darunavir reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential. 
Neklinički podaci o darunaviru ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti i kancerogenog potencijala.